Lundbeckfond Invest A/S 4
4 · Trevi Therapeutics, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4
Lundbeckfond Invest A/S
10% Owner
Transactions
- Conversion
Series C Preferred Stock
2019-05-09−6,849,315→ 0 total→ Common Stock (776,544 underlying) - Conversion
Common Stock
2019-05-09+776,544→ 776,544 total - Purchase
Common Stock
2019-05-09$10.00/sh+375,000$3,750,000→ 1,151,544 total
Footnotes (1)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.